$RLYP (Relypsa, Inc.)

$RLYP {{ '2016-07-26T10:34:24+0000' | timeago}} • Announcement

WeissLaw said it is investigating whether $RLYP's Board acted in the best interests of its shareholders to maximize shareholder value prior to entering into agreement. At least one analyst had set a target price of $51 per share.

$AMAG {{ '2018-01-08T15:32:45+0000' | timeago}} • Announcement

Pharma firm $AMAG said it expects double-digit revenue growth in fiscal 2017, and strong bottomline cash generation. The company expects 4Q17 revenues to be between $155MM and $162MM, and sees an operating loss of $6-$16MM. FY17 revenue is estimated to be in the $607-$614MM range. Full year operating loss is forecasted between $292MM and $302MM.

$CELG {{ '2017-12-11T13:33:44+0000' | timeago}} • Announcement

$CELG and its partner $BLUE announce results of Phase I study of bb2121, a therapy that is jointly developed by both the companies for treating blood cancer. Of the 18 patients enrolled for this trial, 56% achieved complete response and only one patient (6%) didn't respond to the treatment.

$CELG {{ '2017-11-16T14:30:32+0000' | timeago}} • Announcement

$CELG and its partner $BLUE reported that FDA granted Breakthrough Therapy Designation, which will expedite the review of the plasma cell cancer treating therapy. This was based on the preliminary data from the ongoing phase 1 study of the therapy. In March 2013, Celgene and Bluebird Bio entered into a strategic alliance in the field of oncology.

$LHCG {{ '2017-11-16T14:14:41+0000' | timeago}} • Announcement

$LHCG-$AFAM merger will create a nationwide provider of in-home healthcare services. The combined company will have 781 locations in 36 states with more than 31,000 employees and revenue of $1.8Bil and adjusted EBITDA of approx. $145MM for the trailing 12-month period ended Sept. 30, 2017.

$LHCG {{ '2017-11-16T14:13:01+0000' | timeago}} • Announcement

$LHCG and $AFAM have agreed to combine in an all-stock merger of equals transaction. Almost Family shareholders will receive 0.9150 shares of LHC Group for each existing Almost Family share. Upon closing of the transaction, LHC Group shareholders will own 58.5% and Almost Family shareholders will own 41.5% of the combined company.

$AMAG {{ '2017-11-06T14:14:12+0000' | timeago}} • Announcement

Pharma company $AMAG said data from its phase-3 study of Feraheme and Injectafer showed that patients treated with Feraheme were markedly less likely to develop severe hypophosphatemia compared to those treated with Injectafer. The study was conducted to assess the impact of the use of intravenous iron treatment on phosphate metabolism.

$MDCO {{ '2017-11-06T13:48:22+0000' | timeago}} • Announcement

$MDCO has initiated the phase-3 clinical program for inclisiran, a formulation for the treatment of atherosclerotic cardiovascular disease, in association with $ALNY. Patient dosing in the ORION-11 clinical trial began on November 1. The company expects data from the trials will support the submission of a New Drug Application by the end of 2019.

$AMAG {{ '2017-09-29T12:41:24+0000' | timeago}} • Announcement

$AMAG announced the appointment of Tracy Palmer Berns as Chief Compliance Officer, with immediate effect. She will report to Joseph Vittiglio, General Counsel and SVP of Legal Affairs and Quality. Berns was the VP of Ethics and Compliance at the Minimally Invasive Therapies Group at $MDT.

$AMAG {{ '2017-09-07T13:58:27+0000' | timeago}} • Announcement

$AMAG appointed Laura Williams as SVP of clinical development, effective immediately. She will report to Julie Krop, M.D., chief medical officer and SVP of clinical development and regulatory affairs at $AMAG. Prior to joining $AMAG, she served as VP of clinical development at Myovant Sciences.

$MDCO {{ '2017-08-28T12:09:36+0000' | timeago}} • Announcement

$MDCO and $ALNY announced positive data from the ORION-1 Phase II study of Inclisiran, an investigational, drug for the treatment of high cholesterol. The companies added that there were no deaths or serious adverse events during the extended observation period.

$AMAG {{ '2017-08-08T16:06:08+0000' | timeago}} • Announcement

$AMAG appointed Oscar Sanchez as VP of quality effective immediately. He will report to Joseph Vittiglio, general counsel and SVP of legal affairs and quality.

$AMAG {{ '2017-08-03T16:39:43+0000' | timeago}} • Announcement

$AMAG completed submission to FDA to broaden existing label for Feraheme (ferumoxytol) to include treatment of all adults with iron deficiency anemia (IDA) who have intolerance or unsatisfactory response to oral iron. $AMAG anticipates FDA decision on filing in 1H18. The current indication is limited to treatment of IDA with chronic kidney disease.

$AMAG {{ '2017-07-24T16:26:48+0000' | timeago}} • Announcement

$AMAG announced the commercial availability of Intrarosa (prasterone) in the US. Intrarosa is the first and only FDA-approved, local non-estrogen product for the treatment of moderate to severe dyspareunia (pain during intercourse) due to menopause.

$AMAG {{ '2017-06-26T12:43:06+0000' | timeago}} • Announcement

$AMAG said that the U.S. FDA has accepted the supplemental new drug application (sNDA) for the Makena subcutaneous auto-injector. The agency established a Prescription Drug User Fee Act target action date of Feb. 14, 2018. The FDA acknowledged the filing of sNDA is subject to a standard 10-month review against a 6-month review communicated earlier.

$BLUE {{ '2017-06-05T16:32:59+0000' | timeago}} • Announcement

$BLUE and $CELG said updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

$AMAG {{ '2017-05-16T12:17:47+0000' | timeago}} • Announcement

$AMAG appointed Helen Milton to the role of VP of regulatory affairs. Dr. Milton will have responsibility for $AMAG’s regulatory activities, including leading the strategic direction and regulatory approach for all products.

$AMAG {{ '2017-05-15T12:24:13+0000' | timeago}} • Announcement

$AMAG announced that it has paid in full the remaining balance of $321MM of its term loan, which was due in 2021. “With the completion of these transactions and expected EBITDA generation from our business operations, including anticipated future milestone payments, we expect to end 2017 with more than $300 million of cash,” said CFO Ted Myles.

$AMAG {{ '2017-05-05T14:14:15+0000' | timeago}} • Announcement

$AMAG priced $300MM of 3.25% Convertible Senior Notes due 2022 in an underwritten public offering. $AMAG lifted the size of the offering from the originally announced $250MM. The offering is expected to close on May 10, 2017

$AMAG {{ '2017-05-04T19:03:57+0000' | timeago}} • Announcement

$AMAG plans to offer $250MM of Convertible Senior Notes due 2022 in an underwritten public offering. $AMAG expects to grant the underwriters an option to purchase, exercisable within a 30-day period, up to an additional $37.5MM of notes, solely to cover over-allotments, if any.

$AMAG {{ '2017-04-25T22:00:07+0000' | timeago}} • Announcement

$AMAG has appointed Arpad Simon, to the role of VP of pharmacovigilance. Prior to joining AMAG, he served in executive-level pharmacovigilance roles at numerous companies including $PFE.

Recent Transcripts

ATEC (Alphatec Holdings, Inc.)
Thursday, November 9 2017 - 9:30pm
CGIX (Cancer Genetics, Inc.)
Thursday, November 9 2017 - 1:30pm
ALQA (Alliqua BioMedical, Inc.)
Thursday, November 9 2017 - 1:00pm
ALNY (Alnylam Pharmaceuticals, Inc.)
Tuesday, November 7 2017 - 9:30pm
CARA (Cara Therapeutics Inc.)
Thursday, November 2 2017 - 8:30pm
ALIM (Alimera Sciences, Inc.)
Thursday, November 2 2017 - 1:00pm
AMAG (AMAG Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 12:00pm
BLUE (bluebird bio, Inc.)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, October 26 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
CGIX (Cancer Genetics, Inc.)
Monday, August 14 2017 - 9:00pm
ATEC (Alphatec Holdings, Inc.)
Thursday, August 10 2017 - 8:30pm
ALQA (Alliqua BioMedical, Inc.)
Thursday, August 10 2017 - 12:00pm
ALNY (Alnylam Pharmaceuticals, Inc.)
Wednesday, August 9 2017 - 8:30pm
CARA (Cara Therapeutics Inc.)
Thursday, August 3 2017 - 8:30pm
ALIM (Alimera Sciences, Inc.)
Thursday, August 3 2017 - 1:00pm
AMAG (AMAG Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, August 2 2017 - 12:00pm

AlphaGraphics you may like